Exosomes-derived T-cell co-stimulator and indoleamine 2,3-dioxygenase 1 levels in peripheral blood can predict the occurrence of immune-related adverse events in gastric cancer patients undergoing immunotherapy (Jiang et al., 2022). This evidence concerns the gene IDO1 and gastric cancer.